Featured Research

from universities, journals, and other organizations

Patients with gluten intolerance: New therapies possible

Date:
April 1, 2014
Source:
McMaster University
Summary:
Elafin, by interacting with the transglutaminase 2 enzyme, decreased the enzymatic reaction that increases the toxicity of peptides derived from gluten, a new study has shown. The research has implications beyond celiac disease, as gluten intolerance has been reported in patients who do not have celiac disease (non-celiac gluten sensitivity).

Researchers at McMaster University have discovered a key molecule that could lead to new therapies for people with celiac disease, an often painful and currently untreatable autoimmune disorder.

Celiac disease is a food sensitivity to dietary gluten contained in cereals. In people who are genetically predisposed, gluten containing food will trigger an immune response that leads to destruction of the intestinal lining, abdominal pain, changes in bowel habits, malnutrition and many other symptoms that include anemia, and neurological problems.

People with this disease cannot eat food containing wheat, rye or barley, which is a main source of protein intake in the western diet.

Researchers in the Farncombe Family Digestive Health Research Institute at McMaster University have discovered that a molecule, elafin, which is present in the intestine of healthy individuals, is significantly decreased in patients with celiac disease. The research was published in The American Journal of Gastroenterology.

When people with celiac disease eat food containing gluten, the digestive enzymes cannot digest it, and left over peptides from digestion induce inflammation. This inflammation is further amplified by an enzyme called tissue transglutaminase 2.

An intriguing finding of the research, say scientists, was that elafin, by interacting with the transglutaminase 2 enzyme, decreased the enzymatic reaction that increases the toxicity of peptides derived from gluten. In studies with mice, the researchers found that the administration of the elafin molecule protects the intestinal lining of the upper gut that is damaged by gluten.

Following a gluten-free diet is very difficult, because gluten is used not only in the food industry but in the cosmetic and pharmaceutical industries as a common, low cost filler.

“People who have to strictly avoid gluten for life often find this very difficult due to these hidden sources,” said Elena Verdu, associate professor of Medicine in the Michael G. DeGroote School of Medicine. “There is a great need for a therapy that will protect patients with celiac disease from these accidental contaminations.”

Verdu says the results raise the possibility of elafin administration or replacement as a new adjuvant therapy to the gluten free diet. “This would add flexibility to a restrictive lifelong diet, and increase patients’ quality of life and potentially accelerate the healing of celiac lesions.”

The research has implications beyond celiac disease.

Recently, gluten intolerance has been reported in patients who do not have celiac disease (non-celiac gluten sensitivity).

Development of new therapies such as this one could help in the management of common gastrointestinal disorders such as irritable bowel syndrome that could be also triggered by wheat containing food.


Story Source:

The above story is based on materials provided by McMaster University. Note: Materials may be edited for content and length.


Cite This Page:

McMaster University. "Patients with gluten intolerance: New therapies possible." ScienceDaily. ScienceDaily, 1 April 2014. <www.sciencedaily.com/releases/2014/04/140401101423.htm>.
McMaster University. (2014, April 1). Patients with gluten intolerance: New therapies possible. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2014/04/140401101423.htm
McMaster University. "Patients with gluten intolerance: New therapies possible." ScienceDaily. www.sciencedaily.com/releases/2014/04/140401101423.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins